What is Rondimen used for?

Rondimen is indicated for Obesity.

What development phase is Rondimen in?

Rondimen is FDA-approved (marketed).

What is the generic name of Rondimen?

MEFENOREX is the generic (nonproprietary) name of Rondimen.

Last reviewed 2026-04-20 · How we verify

Rondimen (MEFENOREX)

FDA-approved withdrawn Small molecule Quality 20/100

Mefenorex (Rondimen) is a marketed obesity treatment that operates by blocking the reabsorption of neurotransmitters involved in appetite and metabolism regulation. Its key competitive advantage lies in its unique mechanism of action and the patent protection extending to 2028, which may limit generic competition. However, the primary risk is the presence of multiple off-patent competitors such as phentermine and diethylpropion, which could erode market share.

At a glance

Generic name	MEFENOREX
Drug class	mefenorex
Modality	Small molecule
Therapeutic area	Metabolic
Phase	FDA-approved
Annual revenue	172

Approved indications

Obesity

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
SEC EDGAR	Revenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Rondimen CI brief — competitive landscape report
Rondimen updates RSS · CI watch RSS